Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
Bluebird Bio
BLUE
BLUE
$128.34
-$2.46
-1.9%
BATS BZX Real Time Price as of May 17, 2019, 4:30 p.m.
View Interactive BLUE Charts
Bluebird Bio is a development-stage biotechnology company focused on gene therapy, gene editing, and cancer immunotherapy.
News & Analysis: Bluebird Bio
The Fool has written over 200 articles on Bluebird Bio.
All
Market Moves
bluebird bio Flies Forward
An approval for Zynteglo is imminent.
How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
A new payment proposal that directly affects hospitals could also boost sales of some expensive new cancer therapies.
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Here's Why Shares of bluebird bio Slumped Today
No-news anxiety-selling seems to be to blame for the biotech's woes.
3 High-Growth Genomics Stocks You Can Buy
These fast-growing companies are leveraging advances in genetic insight in ways that could pay off big for investors.
2 Blockbuster Gene Therapy Programs to Watch in 2019
A thousand gene therapies in development could get a lot more attention if these two live up to expectations this year.
Here's Why bluebird bio Gained 16.3% in February
The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.
With a Stocked War Chest, bluebird bio Presses On
The biotech is on the verge of its first approval, with three more in the works.
Here's Why Gene Therapy Stocks Are Soaring Today
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
